Deutsche Bank Reiterates Hold Rating, $104 PT on Mednax Following In-Line Q3 Results, Q4 Guidance

In a report published Thursday, Deutsche Bank analyst Darren Lehrich reiterated a Hold rating and $104.00 price target on

. In the report, Deutsche Bank noted, “Overall, Q3 results were mostly in-line with expectations, with EPS $1.52 vs. guidance of $1.46-$1.51 and Street consensus $1.48 / DBe $1.46. EPS was helped $0.06/sh by parity payments (vs. guidance $0.05/sh) and $0.04/sh by lower tax rate. Q4 guidance was initiated in-line with expectations. MD also announced a shelf filing, which we believe signals bigger M&A activity in development pipeline.” Mednax closed on Wednesday at $105.75.